Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemotherapy in Early HER2-Negative Breast Cancer
NCT00887536Phase 3Completed
- Sponsor
- NSABP Foundation
- Start
- May 2009
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in breast cancer (3 arms), sponsored by NSABP Foundation. Primary endpoint: Invasive Disease-Free Survival. Started May 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00887536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887536.